TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7237927

Group type: EXPERIMENTAL
Intervention: Low cholesterol fat-modified diet (mean 200 mg/day, polyunsaturated/saturated fat ratio of 1.0, 43% of total energy from fat)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (age and sex matched normal subjects)
Number of subjects: 24
Study: 31779672

Group type: EXPERIMENTAL
Intervention: Cryo-RDN treatment
Number of subjects: 200

Group type: COMPARATOR
Intervention: Sham treatment (renal angiography alone)
Number of subjects: 200
Study: 28425560

Group type: EXPERIMENTAL
Intervention: 3D displays
Number of subjects: 0
Study: 25580809

Group type: EXPERIMENTAL
Intervention: Simulation-based training followed by clinical training (n = 18)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Clinical training only (n = 15)
Number of subjects: 33
Study: 25064422

Group type: EXPERIMENTAL
Intervention: Slow-release oral morphine (SROM)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 276
Study: 22077869

Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone 400 mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 19244261

Group type: EXPERIMENTAL
Intervention: Sevoflurane via vaporizer
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sevoflurane via AnaConDa
Number of subjects: 16
Study: 17671114

Group type: EXPERIMENTAL
Intervention: 5-aza-2'-deoxycytidine
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: RAMP2
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Knockdown of RAMP2 by RNA interference
Number of subjects: 54

Group type: COMPARATOR
Intervention: Methylation of RAMP2, EFEMP1, and Dutt1
Number of subjects: 54
Study: 15310347

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 47
Study: 11124777

Group type: EXPERIMENTAL
Intervention: Behavioural intervention
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 610

Group type: COMPARATOR
Intervention: Control (existing services)
Number of subjects: 610
Study: 9594474

Group type: EXPERIMENTAL
Intervention: Single-visit RCT
Number of subjects: 291

Group type: COMPARATOR
Intervention: Multiple-visit RCT
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Nonvital pulp treatment
Number of subjects: 291
Study: 7983882

Group type: EXPERIMENTAL
Intervention: Leukocyte-depleted terminal cardioplegic solution (n = 10)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Terminal cardioplegic solution (n = 10)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Whole blood (n = 10)
Number of subjects: 68
Study: 2992785

Group type: EXPERIMENTAL
Intervention: vindesine plus cisplatin
Number of subjects: 58

Group type: COMPARATOR
Intervention: vindesine plus mitomycin
Number of subjects: 58
Study: 31602689

Group type: EXPERIMENTAL
Intervention: BaSICS intervention (n = 44)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Assessment-only control condition (n = 40)
Number of subjects: 84
Study: 29806665

Group type: EXPERIMENTAL
Intervention: 6 mm long × 4 mm wide implants
Number of subjects: 40

Group type: COMPARATOR
Intervention: Implants of at least 10 mm long
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 6 mm long implants
Number of subjects: 40
Study: 26774401

Group type: EXPERIMENTAL
Intervention: GH replacement
Number of subjects: 23

Group type: COMPARATOR
Intervention: No GH replacement (control)
Number of subjects: 23
Study: 25370899

Group type: EXPERIMENTAL
Intervention: FOLFOX-4 or XELOX adjuvant chemotherapy
Number of subjects: 517
Study: 22486301

Group type: EXPERIMENTAL
Intervention: Video-assisted thoracic sympathectomy (VATS)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 45
Study: 20452894

Group type: EXPERIMENTAL
Intervention: HAART (nucleoside free)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: HAART (nucleoside containing)
Number of subjects: 168

Group type: COMPARATOR
Intervention: No HAART
Number of subjects: 168

Group type: COMPARATOR
Intervention: No HAART (HIV-negative)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: HAART (HIV-positive)
Number of subjects: 168

Group type: COMPARATOR
Intervention: HIV-negative
Number of subjects: 168
Study: 18622282

Group type: EXPERIMENTAL
Intervention: Fluvastatin 80 mg/day
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 17914655

Group type: EXPERIMENTAL
Intervention: argon plasma coagulation plus imiquimod cream
Number of subjects: 49

Group type: COMPARATOR
Intervention: argon plasma coagulation alone
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: HIV-positive patients with combination therapy
Number of subjects: 49

Group type: COMPARATOR
Intervention: HIV-positive patients with monotherapy
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: HIV-negative patients
Number of subjects: 49
Study: 14681347

Group type: EXPERIMENTAL
Intervention: St. John's wort (SJW) 300 mg three times a day for 15 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Theophylline 400 mg single oral dose
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: St. John's wort (SJW)
Number of subjects: 12
Study: 11010695

Group type: EXPERIMENTAL
Intervention: Factors associated with positive perceived health
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Mobility and better physical performance status
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Absence of depression
Number of subjects: 700

Group type: COMPARATOR
Intervention: Gender, limitations in daily living activities, dementia, and utilization of services
Number of subjects: 700
Study: 9403274

Group type: EXPERIMENTAL
Intervention: Cefditoren pivoxil (ME1207) 50 mg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Cefditoren pivoxil (ME1207) 100 mg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Cefditoren pivoxil (ME1207) 200 mg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Cefditoren pivoxil (ME1207) 300 mg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Cefditoren pivoxil (ME1207) 500 mg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Cefditoren pivoxil (ME1207) 200 mg after a meal
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Cefditoren pivoxil (ME1207) 200 mg every 12 h for 7 days
Number of subjects: 4
Study: 1488874

Group type: EXPERIMENTAL
Intervention: Long-term lowering of glucosylated hemoglobin (HbA1%)
Number of subjects: 45
Study: 3548954

Group type: EXPERIMENTAL
Intervention: Methylphenidate (chronic phase)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Choline chloride (chronic phase)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylphenidate plus choline chloride (chronic phase)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral placebo (chronic phase)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylphenidate (acute phase)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physostigmine (acute phase)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral placebo (acute phase)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular placebo (acute phase)
Number of subjects: 0
Study: 30561029

Group type: EXPERIMENTAL
Intervention: Psyllium group (Mucilin SF 15.2 g/L added to Blendera)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (Blendera, fiber-free formula)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Psyllium group
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 83
Study: 27720494

Group type: EXPERIMENTAL
Intervention: Autologous blood harvest (ABH) with simultaneous replacement of blood volume with 1:1 colloid (Tetraspan)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no ABH)
Number of subjects: 50
Study: 27532828

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 300

Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 300
Study: 25079708

Group type: EXPERIMENTAL
Intervention: Higher baseline depression symptoms
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Higher PTSD symptoms
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Higher traumatic grief symptoms
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Increased anxiety symptoms
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Decreased depression symptoms
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Decreased PTSD symptoms
Number of subjects: 96
Study: 22458247

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced total-body CT scan (head to pelvis) during the primary survey
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional trauma imaging protocols supplemented with selective CT scanning
Number of subjects: 0
Study: 19735370

Group type: EXPERIMENTAL
Intervention: Intervention (BioSand Filter)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control (normal practices)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Intervention (BioSand Filter) among sub-group using unimproved water sources
Number of subjects: 59
Study: 17526594

Group type: EXPERIMENTAL
Intervention: After sales service with supportive supervision
Number of subjects: 713

Group type: EXPERIMENTAL
Intervention: Prospective reimbursement
Number of subjects: 713

Group type: EXPERIMENTAL
Intervention: Both packages (after sales service with supportive supervision and prospective reimbursement)
Number of subjects: 713

Group type: COMPARATOR
Intervention: Neither package (control group)
Number of subjects: 713

Group type: EXPERIMENTAL
Intervention: Overall interventions
Number of subjects: 713
Study: 15082421

Group type: EXPERIMENTAL
Intervention: Palm oil infusion
Number of subjects: 14

Group type: COMPARATOR
Intervention: Safflower oil infusion
Number of subjects: 14
Study: 12790954

Group type: EXPERIMENTAL
Intervention: Anal plug (two sizes tested for 2 weeks each)
Number of subjects: 20
Study: 10453752

Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (DSCG)
Number of subjects: 3

Group type: COMPARATOR
Intervention: No treatment (DSCG non-treated patients)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 3
Study: 7884019

Group type: EXPERIMENTAL
Intervention: Amitriptyline 150 mg per day
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Doxepin 150 mg per day
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Fluvoxamine 150 mg per day
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg per day
Number of subjects: 32
Study: 3067744

Group type: EXPERIMENTAL
Intervention: Carteolol 2% twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Timolol 0.5%
Number of subjects: 0
Study: 29191844

Group type: EXPERIMENTAL
Intervention: Predictive low-glucose management (PLGM)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Sensor-augmented pump therapy (SAPT)
Number of subjects: 154
Study: 27228377

Group type: EXPERIMENTAL
Intervention: Percutaneous Endoscopic Gastrostomy (PEG) for 4 weeks or more
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nasogastric Tube for 4 weeks
Number of subjects: 40
Study: 23652840

Group type: EXPERIMENTAL
Intervention: Italian version of Liverpool Care Pathway
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control (before implementation)
Number of subjects: 79
Study: 23516031

Group type: EXPERIMENTAL
Intervention: Periarticular anesthetic infiltration (PAI)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Femoral nerve block
Number of subjects: 60
Study: 20543275

Group type: EXPERIMENTAL
Intervention: Immersive virtual reality (VR) environment with six video vignettes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-immersive flat screen display
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presence in VR environment
Number of subjects: 0
Study: 18795647

Group type: EXPERIMENTAL
Intervention: CPC/ZG gel (0.10% cetylpyridinium chloride and 0.592% zinc gluconate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control gel (0% CPC and 0.592% ZG)
Number of subjects: 0
Study: 16636029

Group type: EXPERIMENTAL
Intervention: Doxapram hydrochloride 1 mg.kg(‐1) iv
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 60
Study: 12100930

Group type: EXPERIMENTAL
Intervention: 10 mL of 2% lidocaine gel intrarectally
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 5 mL of 1% lidocaine solution periprostatic injection
Number of subjects: 150

Group type: COMPARATOR
Intervention: No anesthetic (control group)
Number of subjects: 150
Study: 10197572

Group type: EXPERIMENTAL
Intervention: Physical training (4 months duration, 4 days/week attendance, 40-minute sessions, mean heart rate 157 +/- 7 beats/min, mean energy expenditure 946 +/- 201 kJ/session)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 71
Study: 7750592

Group type: EXPERIMENTAL
Intervention: Ethanol (1 mL/kg 95% ethanol)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Carbohydrate placebo punch
Number of subjects: 12
Study: 2328553

Group type: EXPERIMENTAL
Intervention: WEB-2086 (40 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6931307

Group type: EXPERIMENTAL
Intervention: MeCCNU and VCR (vincristine)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MeCCNU and DTIC (5‐(3,3‐dimethyl‐1‐triazeno)‐imidazole‐4‐carboxamide)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MeCCNU, DTIC, and VCR
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: MeCCNU and B‐2‐deoxythioguanosine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy containing MeCCNU
Number of subjects: 40
Study: 30985546

Group type: EXPERIMENTAL
Intervention: Maternal viral load >10,000 copies/mL
Number of subjects: 2275

Group type: EXPERIMENTAL
Intervention: Maternal viral load <1000 copies/mL
Number of subjects: 2275

Group type: EXPERIMENTAL
Intervention: Maternal viral load 1000.1-10,000 copies/mL
Number of subjects: 2275

Group type: EXPERIMENTAL
Intervention: Food shortage
Number of subjects: 2275

Group type: EXPERIMENTAL
Intervention: Sexually transmitted infection (STI) in the past year
Number of subjects: 2275

Group type: EXPERIMENTAL
Intervention: History of herpes zoster
Number of subjects: 2275

Group type: EXPERIMENTAL
Intervention: History of tuberculosis
Number of subjects: 2275
Study: 29126030

Group type: EXPERIMENTAL
Intervention: Fish oil (1g/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 50
Study: 25887884

Group type: EXPERIMENTAL
Intervention: Short stitch suture technique
Number of subjects: 468

Group type: COMPARATOR
Intervention: Long stitch suture technique
Number of subjects: 468
Study: 23896581

Group type: EXPERIMENTAL
Intervention: 2010-2011 seasonal trivalent influenza vaccine (TIV) manufactured by GlaxoSmithKline
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: 2010-2011 seasonal trivalent influenza vaccine (TIV) manufactured by Sanofi Pasteur
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: 2010-2011 seasonal trivalent influenza vaccine (TIV) manufactured by Sinovac Biotech
Number of subjects: 900

Group type: COMPARATOR
Intervention: 2010-2011 seasonal trivalent influenza vaccine (TIV)
Number of subjects: 900
Study: 20801515

Group type: EXPERIMENTAL
Intervention: Confocal microscopy
Number of subjects: 146
Study: 19706087

Group type: EXPERIMENTAL
Intervention: Emollient application alone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bathing with immediate emollient application
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bathing and delayed emollient application
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bathing alone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combination bathing and emollient application regimens
Number of subjects: 10

Group type: COMPARATOR
Intervention: Bathing without moisturizer
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bathing followed by moisturizer application
Number of subjects: 10
Study: 17920918

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg daily)
Number of subjects: 41276

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41276
Study: 14688176

Group type: EXPERIMENTAL
Intervention: Goserelin plus anastrozole for 6 months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Goserelin alone for 6 months
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Goserelin plus anastrozole
Number of subjects: 80

Group type: COMPARATOR
Intervention: Goserelin alone
Number of subjects: 80
Study: 11207037

Group type: EXPERIMENTAL
Intervention: New formula for estimating GFR using patient characteristics
Number of subjects: 62

Group type: COMPARATOR
Intervention: Cockcroft and Gault formula
Number of subjects: 62

Group type: COMPARATOR
Intervention: Jelliffe formula
Number of subjects: 62
Study: 9715553

Group type: EXPERIMENTAL
Intervention: Twins
Number of subjects: 42

Group type: COMPARATOR
Intervention: Normal singleton controls
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: LBW twins
Number of subjects: 42

Group type: COMPARATOR
Intervention: Matched high risk singletons
Number of subjects: 42
Study: 8373942

Group type: EXPERIMENTAL
Intervention: 0.75 ml/kg alcohol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 3538520

Group type: EXPERIMENTAL
Intervention: argon laser photocoagulation
Number of subjects: 38
Study: 31694439

Group type: EXPERIMENTAL
Intervention: GOLD 2 patients
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: GOLD 3 patients
Number of subjects: 542

Group type: COMPARATOR
Intervention: No assigned GP
Number of subjects: 542

Group type: COMPARATOR
Intervention: No contact with COPD nurse in the past 12 months
Number of subjects: 542

Group type: COMPARATOR
Intervention: Continuity in patient-GP consultations
Number of subjects: 542

Group type: COMPARATOR
Intervention: Contact with a COPD nurse
Number of subjects: 542
Study: 29146401

Group type: EXPERIMENTAL
Intervention: Neratinib 240 mg/day for 1 year
Number of subjects: 2840

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2840

Group type: EXPERIMENTAL
Intervention: Neratinib
Number of subjects: 2840
Study: 25990305

Group type: EXPERIMENTAL
Intervention: Intravenous bolus of MRA therapy (potassium canrenoate 200 mg) followed by oral spironolactone 50 mg once daily for 3 months
Number of subjects: 150

Group type: COMPARATOR
Intervention: Matching placebo prior to PPCI followed by matching placebo for 3 months
Number of subjects: 150
Study: 23053125

Group type: EXPERIMENTAL
Intervention: Low glycogen (LG) exercise
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal glycogen (NG) exercise
Number of subjects: 10
Study: 21604965

Group type: EXPERIMENTAL
Intervention: Good practice intervention for childhood obesity (8 hours contact over 26 weeks, group based)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Good practice intervention for childhood obesity
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 107
Study: 19380329

Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg
Number of subjects: 34701

Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg
Number of subjects: 34701

Group type: COMPARATOR
Intervention: Diclofenac 150 mg
Number of subjects: 34701

Group type: EXPERIMENTAL
Intervention: History of CHF
Number of subjects: 34701

Group type: EXPERIMENTAL
Intervention: Age > or = 65 years
Number of subjects: 34701

Group type: EXPERIMENTAL
Intervention: History of hypertension
Number of subjects: 34701

Group type: EXPERIMENTAL
Intervention: History of diabetes
Number of subjects: 34701
Study: 17005084

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) 100 Hz
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) 2 Hz
Number of subjects: 72

Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 72
Study: 15552355

Group type: EXPERIMENTAL
Intervention: Simultaneous presentation of items for selection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sequential presentation of items for selection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High memory spans
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low memory spans
Number of subjects: 0
Study: 10711616

Group type: EXPERIMENTAL
Intervention: Active chlorhexidine chip plus scaling and root planing (SRP)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) alone
Number of subjects: 45

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) plus placebo chip
Number of subjects: 45
Study: 9371930

Group type: EXPERIMENTAL
Intervention: Optic neuritis treatment
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: No MRI lesions
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Three or more MRI lesions
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: No brain MRI lesions and no history of neurologic symptoms or optic neuritis in the fellow eye
Number of subjects: 388
Study: 1287831

Group type: EXPERIMENTAL
Intervention: Heparin-coated circuit with 50% reduction of systemic heparin bolus
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (standard heparin treatment)
Number of subjects: 20
Study: 4026691

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Number of subjects: 122

Group type: COMPARATOR
Intervention: Betahistine (vasoactive substance)
Number of subjects: 122
Study: 12281505

Group type: EXPERIMENTAL
Intervention: hCG injections (250 IU/day i.m.) for 21 days in OC users
Number of subjects: 82

Group type: COMPARATOR
Intervention: 500 kcal reduction diet for 28 days
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: hCG injections (250 IU/day i.m.)
Number of subjects: 82
Study: 31379301

Group type: EXPERIMENTAL
Intervention: Anterior-to-posterior (AP) non-thrust manipulation (NTM)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Lateral (LAT) non-thrust manipulation (NTM)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Both AP and LAT NTM
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Resting systolic blood pressure (SBP)
Number of subjects: 43
Study: 31060795

Group type: EXPERIMENTAL
Intervention: Interstitial brachytherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ongoing trials
Number of subjects: 0
Study: 29097325

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg dezocine
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg dezocine
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg dezocine
Number of subjects: 390

Group type: COMPARATOR
Intervention: Control group (0.1 mg/kg)
Number of subjects: 390